Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25294900.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2055 and PMC identifier 4433012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Hydroxamic Acids
- Imidazoles
- Indoles
- Lymphoma, Large B-Cell, Diffuse
- Quinolines
- Signal Transduction